Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

XWPharma Completes $40 Million Round for Neurobiology Candidates

publication date: Sep 17, 2020

XWPharma of Wuhan completed a $40 million Series C financing to develop its portfolio of novel neurobiology candidates. XW, which also has operations in Redwood City, California, was previously known as XW Laboratories. In addition, the company announced that Leonard Blum, an industry veteran, will become President and CEO of XW, and will spearhead increased emphasis on US development. The C round was led by Panacea Venture. In its two previous rounds, XW raised $23 million in venture capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital